ReviewTranslational oncology2025
Epigenetic modifiers to enhance the efficacy of immune checkpoint inhibitors for the treatment of melanoma.
Review in Translational oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Overcoming melanoma drug resistance: Mechanisms and clinical progress of oncolytic viruses combined with immune checkpoint inhibitors (Review).Oncology reports · 2026Review
- Travelling Waves in Gene Expression: A Mathematical Model of Cell-State Dynamics in Melanoma.Bulletin of mathematical biology · 2026Article
- Review
- Ferroptosis, pyroptosis, and necroptosis in melanoma: regulatory cell death pathways and their implications for immunotherapy.Frontiers in oncology · 2026Review
- Epigenetic Modulators and Immunotherapy in Malignant Melanoma.Oncology research · 2026Review
- Molecular reprogramming in cutaneous melanoma: the central role of G9a and EZH2 methyltransferase inhibitors in tumor plasticity, immune evasion, and therapeutic resistance.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitor (ICI)-based immunotherapy has significantly improved survival outcomes and radically changed the management of many different types of solid tumors, including melanoma. Almost half of advanced melanoma patients achieve a long-term clinical benefit from ICIs. Unfortunately, the other half of treated patients either rapidly progress or achieve a short-term clinical benefit due to the development of resistance. As a result, novel therapeutic strategies are urgently needed to overcome ICI resistance. Epigenetic alterations affecting the tumor neoantigen presentation system or modifying the tumor microenvironment can mitigate ICI resistance. Several studies have demonstrated that epigenetic alterations are potentially targetable by epigenetic modifiers, laying the foundation for the development of novel therapeutic strategies to overcome ICI resistance. In the present work, we summarize the major epigenetic alterations involved in the pathogenesis of melanoma and their role in ICI resistance. Preclinical evidence supporting the biological rationale for combining epigenetic modifiers with ICIs and an updated overview of the main clinical trials testing epigenetic modifiers for the treatment of melanoma patients will be presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.